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Objectives: The objective of this study was to assess the relation between cancer treatments and incident
cognitive impairment in breast cancer patients, taking into account the levels of anxiety before
treatment.
Materials and methods: We conducted a prospective cohort study with 418 newly diagnosed breast
cancer patients with no cognitive impairment, deﬁned as values at least 1.5 standard deviations below
age- and education-adjusted cut-offs in the Montreal Cognitive Assessment (MoCA), at baseline. The
Hospital Anxiety and Depression Scale and MoCA were used for evaluations before treatment and at 1-
year after diagnosis. We used Poisson regressions to compute adjusted relative risks (RR) and corre-
sponding 95% conﬁdence intervals (95%CI) to identify predictors of cognitive impairment.
Results: The median (Percentile 25, Percentile 75) MoCA score before treatment was 24 (21, 26). A total of
8.1% (95%CI: 5.8, 11.2) of the patients presented incident cognitive impairment during the follow-up.
There was a statistically signiﬁcant interaction between anxiety at baseline and the effect of chemo-
therapy on the incidence of cognitive impairment (P for interaction ¼ 0.028). There was a signiﬁcantly
increased risk of incident cognitive impairment among patients with no anxiety prior to treatment with
schemes including doxorubicin and cyclophosphamide (adjusted RR ¼ 4.22, 95%CI: 1.22, 14.65).
Conclusion: There was a statistically signiﬁcant association between chemotherapy and cognitive
impairment, but only among women with no anxiety at baseline.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
Worldwide, breast cancer is the leading cause of malignant
neoplasms among women, with an estimated 1.67 million new
cases in 2012 [1]. Due to improved access to early diagnosis and
effective treatments [2,3], breast cancer survival increased over the
past years, with the most recent 5-year relative survival estimates
surpassing 80% in several developed countries [4]. The growing
number of women surviving breast cancer for longer periods
highlights the need for a comprehensive assessment of the burden
related to cancer treatment, especially regarding conditions thatda Saúde Pública e Forenses e
de do Porto, Al. Prof. Herna^nimay be associated with some degree of incapacity throughout life.
Breast cancer and its treatment may be accompanied by several
neurological complications [5], which may affect the patients' ca-
pacity to accomplish their daily life activities [6]. Although cogni-
tive impairment has been documented among breast cancer
patients, its aetiology and determinants remain unclear. Chemo-
therapy has been the treatment more consistently associated with
cognitive impairment among breast cancer patients [7e10], and the
pattern of cognitive dysfunction associated with it was named
“chemobrain” [11]. However, heterogeneous results across studies
may reﬂect, to some extent, methodological differences, namely
regarding the deﬁnition of the outcome, the characterization of the
exposure and the control of confounding factors [12,13].
In addition to chemotherapy, many other treatments and con-
ditions have been postulated to be related to cognitive impairment,
namely radiotherapy [14,15], endocrine therapy [16,17], para-
Table 1
Sociodemographic and clinical characteristics of breast cancer patients with normal
cognitive function for their age and education at baseline (N ¼ 418).
N (%)
Agea, years
55 200 (47.8)
>55 218 (52.2)
Educationb, years
4 198 (47.4)
5-9 110 (26.3)
10 110 (26.3)
Anxietyc 159 (38.0)
Depressiond 34 (8.1)
Cancer stage
0 29 (6.9)
I 197 (47.1)
II 132 (31.6)
III 60 (14.4)
Breast surgerye
Breast-conserving 212 (50.7)
Mastectomy 206 (49.3)
Axillary surgeryf [N ¼ 404]
SLNB 265 (65.6)
ALND 139 (34.4)
Chemotherapy 242 (57.9)
Timing
Neoadjuvant 25 (10.3)
Adjuvant 217 (89.7)
Schemes
Doxorubicin þ cyclophosphamideg 50 (20.7)
Doxorubicin þ cyclophosphamide þ docetaxelh 24 (9.9)
5-FU þ epirubicin þ cyclophosphamidei 20 (8.3)
5-FU þ epirubicin þ cyclophosphamide þ docetaxelj 144 (59.5)
Othersk 4 (1.6)
Radiotherapy 303 (72.5)
Brachytherapy 82 (19.6)
Endocrine therapy 351 (84.0)
Immunotherapy 55 (13.2)
ALND, Axillary lymph node dissection; SLNB, Sentinel lymph node biopsy; 5-FU, 5-
Fluorouracil.
a Range: 27e87 years.
b Range: 2e22 years.
c Deﬁned as a score 11 in the anxiety subscale of the Hospital Anxiety and
Depression Scale. Themedian (Percentile 25, Percentile 75) of the whole sample was
9 (6, 12).
d Deﬁned as a score 11 in the depression subscale of the Hospital Anxiety and
Depression Scale. Themedian (Percentile 25, Percentile 75) of the whole sample was
5 (2, 8). Within the group of patients with depression, four patients did not present
anxiety (11.8%) but the remaining 30 cases reached a clinically signiﬁcant score in
the anxiety subscale (88.2%).
e Patients who had both breast-conserving surgery and mastectomy are reported
as mastectomy.
f Patients who had both SLNB and ALND are reported as ALND; does not sum
100.0% because 14 patients only performed breast surgery.
g Four cycles of concomitant doxorubicin (60 mg/m2) and cyclophosphamide
(600 mg/m2).
h Four cycles of concomitant doxorubicin (60 mg/m2) and cyclophosphamide
(600 mg/m2), followed by four cycles of docetaxel (100 mg/m2).
i Six cycles of concomitant 5-FU (500 mg/m2), epirubicin (100 mg/m2), and
cyclophosphamide (500 mg/m2).
j Three cycles of concomitant 5-FU (500 mg/m2), epirubicin (100 mg/m2) and
cyclophosphamide (500mg/m2), followed by three cycles of docetaxel (100mg/m2).
k Four cycles of concomitant doxorubicin (60 mg/m2) and cyclophosphamide
(600mg/m2), followed by four cycles of Paclitaxel (80 mg/m2) (N¼ 1), Four cycles of
concomitant cyclophosphamide (600mg/m2) and docetaxel (75 mg/m2) (N¼ 1), Six
cycles of concomitant docetaxel (75 mg/m2) and carboplatin (212 mg/m2) (N ¼ 1)
and Six cycles of concomitant 5-FU (600 mg/m2), cyclophosphamide (600 mg/m2)
and methotrexate (40 mg/m2) (N ¼ 1).
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cytokines, especially interleukin 1 and 6, and tumour necrosis
factor [19] and also anxiety and depression [10]; however, ﬁndings
are inconsistent.
Although anxiety has not been consistently proven to be a risk
factor for cognitive impairment [10,20,21], cognitive interference
theories suggest that high levels of anxiety are associated with
poorer performance in cognitive tests, due to decreasing atten-
tional control [22,23]. Therefore, we hypothesized that anxiety
prior to treatment may inﬂuence the estimated role of potential
risk factors for cognitive impairment; this may also contribute to
inconsistent ﬁndings across studies, and should be taken into ac-
count in the interpretation of results. We aimed to quantify the
association between cancer treatments and incident cognitive
impairment, in early stage breast cancer patients during the ﬁrst
year of follow-up, taking into account the levels of anxiety before
treatment.
2. Methods
We conducted a prospective cohort study of womenwith newly
diagnosed breast cancer, followed for 1-year, as previously
described in detail [24].
2.1. Assembling of the cohort
Participants were consecutively recruited in 2012, among
women aged 18 years or older, admitted to the Breast Clinic of the
Portuguese Institute of Oncology of Porto (IPO-Porto), Portugal,
with a potential diagnosis of breast cancer (N ¼ 961). We consid-
ered eligible those who were proposed for surgery, with histolog-
ically conﬁrmed breast cancer diagnosed in the previous three
months, not treated with chemotherapy and/or radiotherapy in the
chest or axillary areas for other primary cancers, and capable of
understanding the purpose of the study (N ¼ 588). We excluded
those who refused to participate (N ¼ 2), those with a Montreal
Cognitive Assessment (MoCA) score at least 1.5 standard deviations
below age- and education-adjusted cut-offs for possible cognitive
impairment at baseline [25] (N ¼ 165), and those with stage IV
cancer (N ¼ 2). We further excluded one womanwith missing data
on anxiety at baseline. Data from 418 participants was therefore
available for the present analysis.
2.2. Data collection
Sociodemographic data was collected at baseline, using a
structured questionnaire. Information on breast cancer stage and
treatment were collected from clinical records.
The Hospital Anxiety and Depression Scale (HADS) [26,27] was
used to characterize anxiety and depression at baseline and at 1-
year of follow-up; scores range from 0 to 21, and scores greater
than or equal to 11 in the respective subscales were considered
indicative of clinically signiﬁcant anxiety and/or depression, as
applicable.
The MoCA test was used to evaluate cognitive performance, at
baseline and at the 1-year follow-up evaluation. Incident cognitive
impairment was considered to have occurred during the ﬁrst year
after the initial assessment when the patient's MoCA score (ranging
from 0 to 30) decreased to values at least 1.5 standard deviations
below age- and education-adjusted cut-offs for possible cognitive
impairment [25].
2.3. Statistical analysis
Sample characteristics are presented as counts and proportionsfor categorical variables, and median and percentiles 25 and 75
(P25, P75) for quantitative variables, taking into account the
asymmetry of the corresponding distributions.
We computed cumulative incidence estimates, and the corre-
sponding 95% conﬁdence intervals (95%CI), for cognitive impair-
ment at the 1-year follow-up. Adjusted relative risks (RR) and
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istics of the patients and the occurrence of cognitive impairment
were computed using Poisson regressions. The potential interaction
between anxiety status at baseline and the remaining exposures
was assessed through stratiﬁed analyses by including an interac-
tion term in the regression models. The variables included in each
model are described in the footnotes of each table with these re-
sults; these correspond to those known to be associated with the
exposure and outcome of interest, without being an intermediate
step in this relation, as supported by scientiﬁc literature.
Statistical analyses were conducted using STATA®, version 11.2
(StataCorp, College Station, TX, USA).
2.4. Ethical approval
The study was approved by the Ethics Committee of the IPO-
Porto (CES 406/011) and by the Portuguese Data Protection Au-
thority (Ref. 9469/2012). All participants provided written consent.
3. Results
At baseline, 52.2% of the patients had more than 55 years of age
(range: 27e87) and 73.7% had less than ten years of education
(range: 2e22). A total of 54.0% were diagnosed with breast cancer
at stage 0 or I, about half were submitted to mastectomy and just
over one-third performed axillary lymph node dissection. Most
patients went on to adjuvant treatment, mainly endocrine therapy
(84.0%), radiotherapy (72.5%) and chemotherapy (51.9%) (Table 1).
All patients completed the 1-year follow-up evaluation; themedian
(P25, P75) follow-up time was 371 (362e385) days.
3.1. Anxiety and depression
At baseline, the median scores in the HADS anxiety and
depression subscales were 9 and 5, respectively, corresponding to
proportions of patients scoring 11 of 38.0% and 8.1%, respectively.
At the 1-year follow-up, the median scores in the HADS anxiety
and depression subscales were 7 and 5, respectively. The corre-
sponding proportions of patients who scored 11 were 24.6% and
13.6%, respectively.
3.2. Incidence of cognitive impairment
The median (P25, P75) MoCA score before treatment was 24 (21,
26), and during the ﬁrst year of follow-up, 34 patients presented
incident cognitive impairment (8.1%, 95%CI: 5.8, 11.2). Among those
without anxiety at baseline, the median (P25, P75) MoCA score
before treatment was 24 (22, 27) and the median (P25, P75) vari-
ation in cognitive performance during the follow-up was 1 (1, 2).
Among those with anxiety, the median (P25, P75) was 24 (20, 26)
for the MoCA score at baseline and 0 (1, 2) for the overall
variation.
3.3. Predictors of cognitive impairment during the ﬁrst year of
follow-up
Table 2 presents adjusted RR and the corresponding 95%CI for
the relation between different sociodemographic and clinical
characteristics of the patients and cognitive impairment during the
ﬁrst year after enrolment, overall and according to the levels of
anxiety at baseline. There were no statistically signiﬁcant differ-
ences according to any of the variables considered, when the whole
sample was considered. The presence of anxiety at baseline was not
signiﬁcantly associated with cognitive impairment (RR ¼ 1.43 95%
CI: 0.73, 2.81), but the effect of chemotherapy on cognitiveimpairment was different according to the anxiety levels at base-
line; the RR for chemotherapy was 2.81 among patients with no
anxiety prior to treatment and 0.50 among thosewith anxiety (P for
interaction ¼ 0.028).
Since a statistically signiﬁcant interaction was observed only for
chemotherapy, and an increased risk of cognitive impairment,
though not statistically signiﬁcant, was observed for patients with
no anxiety at baseline, we analysed the relationship between
different chemotherapy schemes and the occurrence of cognitive
impairment among patients without anxiety at baseline, as
detailed in Table 3. There was no signiﬁcant difference in the risk of
cognitive impairment according to the timing of chemotherapy,
especially when RR estimates were further adjusted to the thera-
peutic schemes used (RR ¼ 1.36 95%CI: 0.10, 17.88 for patients
submitted to neoadjuvant and RR ¼ 1.65 95%CI: 0.39, 6.95 for
adjuvant chemotherapy). Concerning the different regimens of
chemotherapy used, women treated with doxorubicin þ
cyclophosphamide (with or without docetaxel) had a four-fold
higher risk of developing cognitive impairment than those not
treated with chemotherapy.
4. Discussion
Anxiety is one of the most common psychiatric disorders
among breast cancer patients [28]. In our study, 38% of the women
were classiﬁed as having clinically signiﬁcant anxiety at baseline,
which is a prevalence higher than those found in the general fe-
male population [29] and in other studies with breast cancer pa-
tients [30,31]. Thompson et al., reported a prevalence of 15.2% in
patients evaluated at least two years after diagnosis [31] and in
another study, Hodgkinson et al., found a prevalence of 9.4% in
women evaluated between two and 10 years after cancer diag-
nosis [30], both using the HADS anxiety subscale and the same
cut-off that we used to deﬁne anxiety. The different moments of
assessment precludes direct comparisons with our results, namely
because a decrease in the scores of anxiety in the two years
following breast cancer diagnosis has been previously reported
[32].
Incident cognitive impairment after one year was observed in
8.1% of the patients, which is lower than in previous prospective
studies evaluating breast cancer patients (range: 15%e80%) [7e10].
The variability in results could be explained by the fact that these
studies did not use normative data to deﬁne the outcome, had
distinct deﬁnitions of cognitive impairment or had different follow-
up periods. Methodological features such as the patients not being
evaluated prior to treatment, and the effect of other medical and
psychological conditions, symptoms of distress such as fatigue, or
anxiety and also pain further contribute to heterogeneous results
regarding the relation between chemotherapy and cognitive
impairment [12,13,33,34].
Anxiety has been studied as a possible predictor of cognitive
dysfunction [20,21], and its interference with performance in
cognitive tests through declining attentional control has been
established [22,23], particularly in those abilities that require a high
degree of concentration and attention, such as executive and
memory function [35e37]. Therefore, cognitive deﬁcits should be
interpreted cautiously in the presence of depressive or anxiety
symptoms [38,39]. In our study, we did not ﬁnd a statistically sig-
niﬁcant association between the presence of anxiety at baseline
and incident cognitive impairment but our results demonstrated
that the effect of chemotherapy on cognitive impairment was
different according to the anxiety levels of patients at baseline, in
accordance with our initial hypothesis that anxiety prior to treat-
ment may inﬂuence the role of potential risk factors for cognitive
impairment. It is unlikely that this resulted from the variation of
Table 2
Adjusted relative risks (RR) and corresponding 95% conﬁdence intervals (95%CI) for the relation between different characteristics of the patients and the occurrence of
cognitive impairmenta during the ﬁrst year after enrolment, according to the patients anxiety status at baseline (N ¼ 418).
All patients (N ¼ 418) Anxiety at baseline P for interaction
No (N ¼ 259) Yes (N ¼ 159)
Patients with cognitive
impairment [N(%)]
Adjusted RR (95%CI) Adjusted RR (95%CI) Adjusted RR (95%CI)
Anxiety at baseline b
No 18 (7.0) 1 (ref.)
Yes 16 (10.1) 1.43 (0.73,2.81)f
Age (years)
55 18 (9.0) 1 (ref.) 1 (ref.) 1 (ref.)
>55 16 (7.3) 0.82 (0.42,1.60) 1.10 (0.43,2.78) 0.59 (0.22,1.63) 0.380
Education (years)
4 15 (7.6) 1 (ref.) 1 (ref.) 1 (ref.)
5-9 10 (9.1) 1.11 (0.47,2.63)d 1.29 (0.38,4.36)d 1.03 (0.31,3.45) d
10 9 (8.2) 1.00 (0.41,2.42)d 1.62 (0.49,5.32)d 0.62 (0.16,2.46)d 0.697
Cancer stage
0/I 21 (9.3) 1 (ref.) 1 (ref.) 1 (ref.)
II/III 13 (6.8) 0.69 (0.34,1.40)e 1.15 (0.45,2.94)e 0.35 (0.11,1.09)e 0.156
Surgeryc [N ¼ 404h]
Breast conserving þ SLNB 17 (10.8) 1 (ref.) 1 (ref.) 1 (ref.)
Breast conserving þ ALND 3 (7.3) 0.82 (0.19,3.60)f 0.69 (0.07,6.69)f 1.30 (0.11,15.28)f
Mastectomy þ SLNB 6 (5.6) 0.54 (0.21,1.40)f 1.19 (0.35,4.02)f 0.15 (0.02,1.18)f
Mastectomy þ ALND 7 (7.1) 0.81 (0.24,2.66)f 1.24 (0.28,5.52)f 0.64 (0.08,5.00)f 0.180
Chemotherapy
No 14 (8.0) 1 (ref.) 1 (ref.) 1 (ref.)
Yes 20 (8.3) 1.23 (0.56,2.71)f 2.81 (0.84,9.44)f 0.50 (0.13,1.60)f 0.028
Radiotherapy [N ¼ 404h]
No 9 (8.0) 1 (ref.) 1 (ref.) 1 (ref.)
Yes 24 (8.2) 0.43 (0.13,1.41)g 0.57 (0.11,3.06)g 0.48 (0.09,2.74)g 0.194
Brachytherapy [N ¼ 404h]
No 24 (7.3) 1 (ref.) 1 (ref.) 1 (ref.)
Yes 9 (11.8) 1.28 (0.53,3.12)g 0.64 (0.12,3.30)g 1.54 (0.49,4.82)g 0.051
Endocrine therapy
No 7 (10.4) 1 (ref.) 1 (ref.) 1 (ref.)
Yes 27 (7.7) 0.76 (0.33,1.74)f 0.41 (0.15,1.10)f 3.08 (0.40,23.68)f 0.124
Immunotherapy
No 31 (8.5) 1 (ref.) 1 (ref.) 1 (ref.)
Yes 3 (5.4) 0.66 (0.20,2.16)f 0.70 (0.16,3.08)f 0.51 (0.07,3.97)f 0.787
ALND, Axillary lymph node dissection; SLNB, Sentinel lymph node biopsy.
a We consider cognitive impairment the decrease from normal values at baseline to abnormal values at 1-year follow-up evaluation.
b Deﬁned as a score 11 in the anxiety subscale of the Hospital Anxiety and Depression Scale.
c Patients who had both mastectomy and breast-conserving surgery are reported as mastectomy and those who had both ALND and SLNB are reported as ALND.
d Adjusted for age.
e Adjusted for age and education.
f Adjusted for age, education and cancer stage.
g Adjusted for age, education, cancer stage and surgery.
h N < 418 because 14 patients only performed breast surgery.
Table 3
Adjusted relative risks (RR) and corresponding 95% conﬁdence intervals (95%CI) for the relation between different chemotherapy schemes and the occurrence of cognitive
impairmenta during the ﬁrst year after enrolment in patients without anxiety at baseline (N ¼ 259).
Patients with cognitive impairment [N(%)] Adjusted RR d (95%CI)
Timing of chemotherapy
No chemotherapy 4 (3.7) 1 (ref.)
Neoadjuvantb 2 (13.3) 5.52 (0.79,38.77)
Adjuvantc 12 (8.8) 2.74 (0.81,9.57)
Chemotherapeutic regimen [N ¼ 257]
No chemotherapy 4 (3.7) 1 (ref.)
Doxorubicin þ cyclophosphamide (with or without docetaxel) 8 (15.4) 4.22 (1.22,14.65)
5-FU þ epirubicin þ cyclophosphamide (with or without docetaxel) 6 (6.1) 1.59 (0.38,6.56)
Docetaxel-based chemotherapy [N ¼ 257]
No chemotherapy 4 (3.7) 1 (ref.)
Without docetaxel 6 (12.8) 3.47 (0.96,12.56)
With docetaxel 8 (7.8) 2.17 (0.54,8.77)
a We consider cognitive impairment the decrease from normal values at baseline to abnormal values at 1-year follow-up evaluation.
b Four cycles of concomitant doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), followed by four cycles of docetaxel (100 mg/m2) or six cycles of concomitant
docetaxel (75 mg/m2) and carboplatin (212 mg/m2).
c Chemotherapeutic schemes other than four cycles of concomitant doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), followed by four cycles of docetaxel
(100 mg/m2) or six cycles of concomitant docetaxel (75 mg/m2) and carboplatin (212 mg/m2).
d Adjusted for age, education and cancer stage.
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anxiety, as the HADS score improved between baseline and the 1-
year follow-up.
Depression has also been associated with cognitive dysfunction
[10,16,40]. In our study, the low number of patients with depression
that did not present anxiety (only four) limits the assessment of the
independent role of depression in the occurrence of cognitive
impairment. Similarly, only 30 patients had both anxiety and
depression, and therefore our ﬁndings related with the effect of
anxiety can hardly be explained by the coexistence of these con-
ditions. In a sensitivity analysis excluding the patients with both
depression and anxiety (data not shown), our results remained
essentially unchanged.
Although an increased risk of cognitive impairment was
observed for different treatment modalities and schemes, the
strongest association was observed for treatment including doxo-
rubicin and cyclophosphamide, regardless of the use of taxanes.
Nevertheless, the fact that all of the patients underwent chemo-
therapy schemes including more than one agent, limits the
assessment of the relative contribution of each agent to the
occurrence of cognitive impairment. Previous studies assessing the
effect of chemotherapeutic schemes with anthracyclines on
cognitive function in breast cancer patients reported inconsistent
results [41,42]. In a recent prospective study, Van Dyk et al. found
no difference in neuropsychological performance during a mean
period of ﬁve years after treatment when those submitted to
anthracyclines were compared to those submitted to
nonanthracycline-based chemotherapy [41]. On the contrary, in a
cross-sectional study, Kesler et al. reported lower memory scores
on average two years after anthracycline treatment when
compared to thosewho underwent other schemes or not submitted
to chemotherapy [42]. The former study did not specify the
anthracycline used and in the latter, all of the patients performed
doxorubicin, which adds to differences in the study design and
strategies of data analysis, precluding direct comparisons with our
results. Also, the lack of sufﬁcient comparative data makes assess-
ment of the relative contribution of each agent almost impossible
and we cannot exclude the possibility that these observed results
were found by chance.
The major methodological strengths of our study are the pro-
spective design, with an evaluation of patients before any treat-
ment and after one year, and a complete follow-up. This study
design allowed for the use of the 1.5 standard deviations cut-off to
deﬁne cognitive impairment instead of the more conservative 2.0
standard deviations, as falling below the cut-off represents a
decline from a previously measured normal cognitive performance.
However, some limitations need to be addressed, especially
regarding the external validity of the results. Our study evaluated
essentially women with early breast cancer, which limits the
generalization to patients with more advanced disease; however, it
eliminates brain metastatic diseases which are known to compro-
mise cognitive functioning. Learning effects may have contributed
to underestimate the incidence of cognitive impairment, which
depended on evaluations with the same instrument at different
moments.
In conclusion, this study shows that the association between
chemotherapy and cognitive impairment was modiﬁed by anxiety
at baseline. Among women with no anxiety at baseline, the risk of
cognitive impairment was four-fold higher among patients un-
dergoing chemotherapy with schemes including doxorubicin and
cyclophosphamide.
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